The Study
The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients
This study gave some people with diabetes a medicine and compared how their blood sugar acted when they took it versus when they took a sugar pill. It found the medicine helped lower blood sugar after meals. But it didn't test if this helps people live longer or feel better over time.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study tested a diabetes medicine called liraglutide that works like a natural hormone to help the body control blood sugar after eating.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 568 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — lowering blood sugar after meals helps prevent complications like nerve and heart damage in people with diabetes.
- 2After taking liraglutide, blood sugar after meals dropped by 25–35%.
- 3Insulin levels went up.
- 4The stomach emptied slower — but only with the higher doses (1.2 mg and 1.8 mg).
- 5The lowest dose (0.6 mg) didn’t help much after meals.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Advances in Therapy
Year
2011
Authors
A. Flint, C. Kapitza, C. Hindsberger, M. Zdravkovic
Related Content
Claims (7)
In people with obesity and prediabetes, liraglutide lowers blood sugar after meals and improves how the body responds to insulin by activating GLP-1 receptors continuously; these effects are not seen with weight loss from diet or sitagliptin, even though those interventions lower fasting blood sugar or raise incretin levels.
Liraglutide lowers blood glucose levels after fasting and after meals in people with obesity and prediabetes by activating GLP-1 receptors, and this effect does not occur with weight loss, DPP-4 inhibition, or increased natural incretin levels.
In adults with type 2 diabetes, taking liraglutide once daily at doses of 0.6, 1.2, or 1.8 mg lowers fasting blood glucose levels by 15% to 25% compared to no treatment, showing a consistent effect on baseline glucose control unrelated to food intake.
In adults with type 2 diabetes, liraglutide at doses of 0.6, 1.2, and 1.8 mg per day increases insulin levels after fasting and after meals compared to a placebo, and this increase in insulin is the main reason blood sugar levels go down.
In adults with type 2 diabetes, taking 0.6 mg of liraglutide per day does not lower blood sugar levels after meals more than would be expected by chance, and higher doses are needed to achieve a measurable effect.
In adults with type 2 diabetes, liraglutide at 1.2 mg and 1.8 mg per day slows the rate at which food leaves the stomach after eating, resulting in lower blood glucose spikes after meals; a dose of 0.6 mg per day does not slow stomach emptying significantly.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.